2nd Quarter - Report

CVS HEALTH (AND SUBSIDIARIES) for CVS HEALTH (AND SUBSIDIARIES)

Firm
Client
Income
—
Expenses
$2,200,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Labor Issues/Antitrust/Workplace LBR

Issues related to the competitive nature of the pharmacy benefit management industry. H.R. 2376/S. 1227, The Prescription Pricing for the People Act of 2019

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
GLEN CHAMBERS —
TEGAN GELFAND —
JOY MCGLAUN —
AMY ROSENBAUM —
SARAH SCHMIDT —

Contacted: Treasury, Dept of; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE; White House Office; Office of the Vice President of the United States

Bills named: H.R. 2376 (116th), S. 1227 (116th)

Health Issues HCR

Issues related to implementation and changes to the Affordable Care Act.

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
GLEN CHAMBERS —
TEGAN GELFAND —
ROSALYN KUMAR —
JOY MCGLAUN —
SHANNON PENBERTHY —
SARAH SCHMIDT —
MELISSA SCHULMAN —

Contacted: White House Office; HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Treasury, Dept of; Office of Management & Budget (OMB); Office of the Vice President of the United States

Taxation/Internal Revenue Code TAX

Issues related to health savings accounts, the health insurance tax, and other taxes included in the Affordable Care Act. S. 80, The Jobs and Premium Protection Act of 2019 S. 172/H.R. 1398, The Health Insurance Tax Relief Act of 2019 H.R. 2213/S. 978, The Work Opportunity Tax Credit and Jobs Act of 2019 S. 1498, The Chronic Disease Management Act of 2019

LobbyistCovered position, as disclosed
TEGAN GELFAND —
SHANNON PENBERTHY —
SARAH SCHMIDT —
MELISSA SCHULMAN —

Contacted: White House Office; SENATE; Office of Management & Budget (OMB); Treasury, Dept of; Health & Human Services, Dept of (HHS); Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES

Bills named: S. 80 (116th), S. 978 (116th), S. 172 (116th), H.R. 2213 (116th), S. 1498 (116th), H.R. 1398 (116th)

Copyright/Patent/Trademark CPT

Issues related to barriers to generic drug and biosmiliar market entry including pay-for-delay and REMS. H.R. 985, The Fair Access for Safe and Timely Generics Act of 2019 S. 64, The Preserve Access to Affordable Generics Act of 2019 S. 340/H.R. 965, The Creating and Restoring Equal Access to Equivalent Samples Act of 2019 H.R. 1499, The Protecting Consumer Access to Generic Drugs Act of 2019 S. 659, The Biologic Patent Transparency Act of 2019

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
TEGAN GELFAND —
ROSALYN KUMAR —
JOY MCGLAUN —
SHANNON PENBERTHY —
AMY ROSENBAUM —
SARAH SCHMIDT —
MELISSA SCHULMAN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of the Vice President of the United States; White House Office; SENATE; Treasury, Dept of; Office of Management & Budget (OMB)

Bills named: H.R. 1499 (116th), S. 340 (116th), S. 659 (116th), H.R. 965 (116th), H.R. 985 (116th), S. 64 (116th)

Medicare/Medicaid MMM

Issues related to the Medicare Part D, Medicare Advantage, Medicaid, and ESRD programs. Issues related to HHS Proposed Rule Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Medicare Advantage Advance Rate Notice and Draft Call Letter for 2020 S. 317/H.R. 1226, The Advancing Care for Exceptional Kids Act of 2019 S. 476, The Creating Transparency to Have Drug Rebates Unlocked Act of 2019 H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 H.R. 1034/S. 640, The Phair Pricing Act of 2019 H.R. 1035, The Prescription Drug Price Transparency Act of 2019 H.R. 2296, The Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R. 3408, the Shop Rx Act of 2019

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
GLEN CHAMBERS —
TEGAN GELFAND —
ROSALYN KUMAR —
JOY MCGLAUN —
SHANNON PENBERTHY —
AMY ROSENBAUM —
SARAH SCHMIDT —
MELISSA SCHULMAN —

Contacted: SENATE; White House Office; Office of Management & Budget (OMB); Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Treasury, Dept of

Bills named: H.R. 1035 (116th), S. 317 (116th), H.R. 3408 (116th), H.R. 803 (116th), H.R. 1226 (116th), H.R. 1034 (116th), S. 640 (116th), H.R. 2296 (116th), S. 476 (116th), S. 988 (116th)

Insurance INS

Issues related to employer, small group and individual insurance markets, including surprise billing. H.R. 3107, The Improving Seniors Timely Access to Care Act of 2019 H.R. 3630, The No Surprises Act of 2019 S. 657, The Drug Price Transparency Act of 2019 S. 1323, The Utilizing National Data, Effectively Reforming Standards and Tools, to Address Negative Determinates of Health Act of 2019 S. 1531, The Stopping the Outrageous Practice Of Surprise Medical Bills Act of 2019 S. 1895, The Lower Health Care Costs Act of 2019

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
GLEN CHAMBERS —
TEGAN GELFAND —
ROSALYN KUMAR —
JOY MCGLAUN —
SHANNON PENBERTHY —
AMY ROSENBAUM —
SARAH SCHMIDT —
MELISSA SCHULMAN —

Contacted: Treasury, Dept of; White House Office; Office of Management & Budget (OMB); Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: S. 1895 (116th), H.R. 3630 (116th), S. 1531 (116th), S. 1323 (116th), H.R. 3107 (116th), S. 657 (116th)

Pharmacy PHA

Issues related to medication adherence, drug price transparency, and prescription drug abuse. H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 H.R. 1034/S. 640, The Phair Pricing Act of 2019 H.R. 1035, The Prescription Drug Price Transparency Act of 2019 H.R. 1614/S. 724, The John S. McCain Opioid Addiction Prevention Act of 2019 H.R. 2113, The Prescription Drug Sunshine, Transparency, Accountability and Reporting Act of 2019 H.R. 2115, The Public Disclosure of Drug Pricing Act of 2019 H.R. 2296, The Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R. 3408, the Shop Rx Act of 2019 S. 1895, The Lower Health Care Costs Act of 2019

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
GLEN CHAMBERS —
TEGAN GELFAND —
ROSALYN KUMAR —
JOY MCGLAUN —
SHANNON PENBERTHY —
AMY ROSENBAUM —
SARAH SCHMIDT —
MELISSA SCHULMAN —

Contacted: White House Office; HOUSE OF REPRESENTATIVES; Treasury, Dept of; SENATE; Office of the Vice President of the United States; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Bills named: H.R. 2296 (116th), H.R. 2113 (116th), H.R. 1614 (116th), H.R. 1035 (116th), H.R. 1034 (116th), H.R. 2115 (116th), S. 724 (116th), S. 988 (116th), S. 1895 (116th), H.R. 803 (116th), S. 640 (116th), H.R. 3408 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.